Black Diamond Therapeutics
BDTX
BDTX
73 hedge funds and large institutions have $52.9M invested in Black Diamond Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 26 reducing their positions, and 23 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
73
Holders Change
-13
Holders Change %
-15.12%
% of All Funds
1.23%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
11
Reduced
26
Closed
23
Calls
$947K
Puts
$925K
Net Calls
+$22K
Net Calls Change
+$211K
Top Buyers
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$3.5M |
| 2 |
NM
Newtyn Management
New York
|
+$1.28M |
| 3 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
+$1.25M |
| 4 |
Millennium Management
New York
|
+$609K |
| 5 |
E
Ergoteles
New York
|
+$271K |
Top Sellers
| 1 |
BlackRock
New York
|
-$2.6M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.15M |
| 3 |
State Street
Boston,
Massachusetts
|
-$721K |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$699K |
| 5 |
JPMorgan Chase & Co
New York
|
-$685K |
